glp 1 pro life science GLP-1 Support and metabolic efficiency The expanding benefits of GLP-1

The page leans into comparison and decision support and the details behind cost and coverage

Diabetes Obes Metab 22(3):355364 Ruiz PLD, Stene LC, Bakken IJ, Hberg SE, Birkeland KI, Gulseth HL (2018) Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study

Clinical trials have shown that clients continue to lose weight for a year or the average weight loss over 68 weeks is around 15% of body weight

These insights underscore the need for patient counseling, preventive oral care, and further studies on receptor signaling bias, contributing to personalized approach when using GLP-1RAs